Enjoy complimentary customisation on priority with our Enterprise License!
The Global Human Combination Vaccines market size is estimated to accelerate by USD 6,046.98 million between 2022 and 2027 and the vaccine market size forecast is expected to increase at a CAGR of 8.13%. The emergence of human combination vaccines has increased due to the rise of infectious diseases, the increased population of newborns, and the initiatives taken by the government to sponsor human combination vaccine programs. The human combination vaccines treat different types of diseases such as polio, Haemophilus influenzae, and Hepatitis B vaccines. The vaccine reduced the number of injections required and boost our immunity system. GSK, Merck and Co., and Sanofi are the names of dominant market players taking over 70%-75% of the market share.
Technavio has divided the market into three segments that are type, channel, and geography. The type segment is classified into the inactivated vaccine and the live attenuated vaccine. The channel is bifurcated into hospitals, retailers, and online. And the geography includes key regions including North America, Europe, Asia, and Rest of World. It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, Download the FREE Report Sample
The Covid-19 pandemic had hindered market growth. With a rise in the number of COVID-19 cases in several states, disruptions were anticipated in the healthcare system's ability to continue providing routine preventive and other non-emergency care. Stay at home policy also slowed down the market growth during this period as Covid-19 limited movement outside the home to essential activities. However, in countries such as the US, on March 24, 2020, the CDC posted guidance emphasizing the importance of routine childcare and immunization (measles, mumps, and rubella vaccine), particularly for children aged less than 24 months, when many childhood vaccines are recommended.
Based on type, the human combination vaccines market is segmented into the inactivated vaccine and live attenuated vaccine. The inactivated vaccine segment is leading the market growth among the two segments. The inactivated vaccines segment was valued at USD 8,233.69 million in 2017 and it will continue to grow during the forecast period.
Get a glance at the market contribution of various segments Request a PDF Sample
The inactivation technique provides greater coverage against various diseases. They are developed using pathogen particles that have been destroyed or killed and, therefore, cannot divide. Inactivated vaccines are safer than live vaccines because they cannot imitate a vaccinated individual, resulting in no risk of return to a virulent form capable of causing diseases. The inactivation technique allows the incorporation of viral and bacterial strains into the vaccine. The human combination inactivated vaccines can be subjected to freeze-drying and therefore are easy to store. They can be transported in large quantities across the globe. Considering the numerous advantages, the human combination inactivated vaccines will witness a high adoption rate during the forecast period, thus driving the market growth. Governments globally are continuously increasing the awareness of vaccines. For instance, the United Nations Children Fund (UNICEF), a United Nations agency, and the World Health Organization (WHO) are supporting countries in their efforts to reimagine immunization by restoring services by adhering to hygiene and physical distancing recommendations and providing protective equipment to health workers. Therefore, such initiatives positively impacted the market in 2020 and are expected to continue accelerating growth during the forecast period.
Hospital pharmacies accounted for the largest share of the global human combination vaccines market in 2022, which will continue to remain the largest segment during the forecast period. Vaccine distribution systems in hospitals are classified into in-patient and out-patient. The hospital pharmacist is competent in drug procurement, handling, pricing, and dispensing. Additionally, pharmacists serve as a liaison between patients and doctors and offer vaccine information to the public and all other healthcare professionals. Hospital pharmacists play a critical role in teaching healthcare professionals, family members, and patients about vaccines. Therefore, the hospital segment is expected to be the primary distribution channel for human combination vaccines, which will contribute to the growth of the hospital segment of the global human combination vaccines market during the forecast period.
North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
North America is the largest geographical segment of the global human combination vaccines market in 2022 and will continue to remain the largest segment of the market during the forecast period. The continuous efforts by vendors and national organizations to promote the use of human combination vaccines will drive the growth of the human combination vaccines market in North America during the forecast period. Additionally, the regional market is witnessing an increasing number of initiatives to generate awareness about immunization programs and increase people's access to vaccines, which will also drive market growth during the forecast period.
Despite the challenges posed by the COVID-19 outbreak, the human combination vaccines market in the region received support from organizations like UNICEF, which enabled healthcare workers in the US to carry on their crucial work of safeguarding children from preventable illnesses such as rubella, measles, and tetanus. The CDC also played its part by urging healthcare providers to continue immunizing children during the pandemic and updating its guidelines for patient visits. Consequently, these factors had a positive impact on the market's growth in 2020. Additionally, various pharmaceutical companies were conducting research to develop different combination vaccines for COVID-19, in response to the rising demand for such vaccines. These developments are expected to contribute to the growth of the regional market in the forecast period.
To know more about segments download the sample reports
There is high competition in human combination vaccines. Among several market players, the organization Pfizer stands out among the competitors due to technological innovation and its on-point marketing strategy.
Pfizer- The company provides wide range of human combination vaccines. The company is also known for its discovery, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide.
The vaccine market report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Technavio’s report consists of a holistic analysis of the key development Analysis, development stage, pipeline analysis, FDA approval, market players, their marketing strategies, and powerful innovations to help any client gain a competitive edge.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
The rise in cases of infectious diseases is notably driving the market growth. Infectious diseases are a prevalent cause of sickness and death across the world. Microbes' presence and their capability to reproduce and adjust to changing populations, environments, and technologies pose a persistent threat to public health. Developing countries experience devastating impacts from infectious diseases, resulting in lower survival rates, particularly among children, and hindering economic growth and development prospects. Developed countries also face significant health and economic burdens from infectious diseases. For instance, HIV infects approximately 50,000 people annually in the US, healthcare-associated infections remain a leading cause of preventable deaths, and chronic viral infections and drug-resistant pathogens cause severe and untreatable infections. To address this challenge, the CDC is striving to reduce the incidence of these diseases by ensuring broad immunization coverage and providing access to recommended vaccines for low-income children and adults.
Threat from bioterrorism is a major cause of concern. Bioterrorism involves the deliberate release of pathogens, including bacteria, viruses, fungi, or toxins, which can cause disease or death among living beings, including humans, animals, or plants. The emergence of new contagious diseases due to globalization has increased the potential threat of bioterrorism worldwide. Consequently, the development of new vaccines to combat bioterrorism has become essential, and developed nations are taking appropriate measures to prevent such threats. A bioterror-induced disease outbreak could lead to high demand for vaccines, resulting in the need for mass vaccinations. As a result, research on vaccines against potential bioterrorism agents is increasing, which is expected to boost the growth of the global human combination vaccines market in the forecast period.
The incompatibility of vaccine components can restrain market growth. A combination vaccine is made up of various antigens that provide immunity against different diseases. While some combinations can boost the immune response of one or more components, not all vaccine components are compatible with each other. Incompatibility can lead to vaccine instability or a suboptimal immune response. For example, combining DTaP and IPV in infants reduced the immune response to the P antigen and decreased antibody production for different antigens after two doses, and toward pertussis toxin after three doses. This resulted in a suboptimal response compared to administering these two vaccines separately. To overcome compatibility issues, extensive research with advanced biotechnological tools is necessary to modify combination vaccine immunogenicity. Such incompatibility issues may hinder the growth of the global human combination vaccines market in the forecast period.
To know more about drivers,trends, and challenges download the sample reports
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Human Combination Vaccines Market Customer Landscape
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
|
Human Combination Vaccines Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
168 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 8.13% |
|
Market growth 2023-2027 |
USD 6,046.98 million |
|
Market structure |
Concentrated |
|
YoY growth 2022-2023(%) |
7.45 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 45% |
|
Key countries |
US, Canada, UK, Germany, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Abbott Laboratories, Arabio, Bharat Biotech Ltd., Biological E. Ltd., Cadila Healthcare Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Grifols SA, LG Corp., Meiji Holdings Co. Ltd., Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Panacea Biotec Ltd., Pfizer Inc., PT Bio Farma, Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Walvax Biotechnology Co. Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Get access to Report Sample PDF !
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
